May 16, 2024 7:58am

More economic data to harness share pricing

News: Agenus (AGEN +$0.22 pre-open) will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the FDA to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the critical elements of the program to support a future biologics license application (BLA) submission.

Pre-Open Indications: 2 Sell into Strength, 2 Positive and 1 Negative Indications

If you're buying on strength, you might be jumping onto a sinking ship

A daily analytic discipline is constructed by period updates and specific warnings of emerging situations

Never leave an investor uninformed

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RM

 

Thursday: The pre-open Dow futures are UP +0.06% or (+24 points), the S&P futures are UP +0.09% or (+4 points) as the Nasdaq futures are UP +0.15% or (+27 points)

Stock futures edged marginally Thursday,

European stocks were lower,

Asia-Pacific markets rose.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday: The Dow closed UP +349.89 points or +0.88%, the S&P closed UP +61.47 points or +1.17% while the Nasdaq closed UP +231.21 points or +1.40%

Economic Data Docket: Initial jobless claims, week ending May 11 (233,000 previously);

  • Housing starts month-over-month, April (8.6% expected, -14.7% prior);
  • Building permits month-over-month, April (+1.6% expected, -3.7% prior);
  • Philadelphia Business Outlook, May (8.7 expected, 15.5 prior); Import prices, month-over-month, April (+0.2% expected, +0.4% previously);
  • Export prices, month-over-month, April (+0.2% expected, +0.3% previously);
  • Industrial production, month-over-month, April (+0.2% expected, +0.4% previously)

Prices as measured by the seasonally-adjusted Consumer Price Index (CPI) are now up over 19.4% in the three-plus years since Biden took office.The year-over-year inflation rate when Biden took office was 1.4%. Prices did then rise after Biden's inauguration and reached 9.1% but that peak came in June 2022 after Biden had been in office for over a year.

 

Wednesday’s night’s RegMed Investors (RMi) Closing Bell: “stayed level re a.m. title after soft reading on consumer prices, a deceleration from March. "Core" inflation striped out the cost of food and gas also cooled as retail sales fell flat.” … https://www.regmedinvestors.com/articles/13462

 

Q2/24:  May – 8 positive and 3 negative closes

  • April - 16 negative and 6 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength Indication:

Wednesday, Tuesday, Monday, Friday and last Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Blueprint Medicine (BPMC) closed up +$1.33 after Tuesday’s -$2.59, Monday’s +$1.35, Friday’s -$1.64 after last Thursday’s -$0.44 with a neutral pre-open indication.

BioLife Solutions (BLFS +$0.56 after Tuesday’s +$1.77, Monday’s +$1.12 and Friday’s +$1.53) with a neutral pre-open indication.

 

Negative Indications:

Wednesday, Tuesday, Monday, Friday and last Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed up +$0.30 after Tuesday’s -$0.21, Monday’s +$2.76, Friday’s -$1.28 and last Thursday’s +$0.30 with a neutral pre-open indication.

 

Positive Indication:

Wednesday, Tuesday, Monday, Friday and last Thursday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Agenus (AGEN) closed up +$0.08 with a positive +$0.22 or +2.04% pre-open indication with news of developing novel immunological agents to treat various cancers.

Intellia Therapeutics (NTLA +$0.49 after Tuesday’s +$0.31 after Monday’s +$0.96, Friday’s -$0.40 and Thursday’s +$1.86 with a positive +$0.49 or +1.87% pre-open indication

 

The BOTTOM LINE: The days of being long are not the strongest investing rationale as the cell and gene therapy sector runs out of buyers, it runs into trouble (just like a fire that runs out of wood).

“I’ve been a few miles, and I’ve seen a few things. What I’m trying to do is just say, look, I don’t know everything, but I know some things—let me level with you. Based on my experience … this is what’s happening.”

  • I suggest that it is better to keep your finger on the sell button but, still keep a buy ticket in the other hand!
  • So, trade some ups, don’t be so fast in buying into few bottoms, build cash position.

 

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.